Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

NCT02484430 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02484430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02484430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
April 6, 2017
Completion date
March 5, 2024
Enrollment
16 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia, b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, b acute lymphoblastic leukemia, philadelphia chromosome negative, recurrent adult acute lymphoblastic leukemia, refractory adult acute lymphoblastic leukemia, t acute lymphoblastic leukemia